IC50 (half maximal inhibitory concentration) is the concentration of a substance required to inhibit a biological process or component by 50% of its maximal activity. It is the gold standard pharmacological measure of drug or compound potency, with lower IC50 values indicating higher potency—less drug needed to achieve the same inhibitory effect.
Think of IC50 like finding the exact dimmer switch setting that cuts the brightness of a room to exactly half. You're not turning the lights completely off, and you're not measuring how bright they can get at maximum—you're just finding that precise middle point. If one light bulb requires the dimmer turned to "2" to reach half brightness, but another identical-looking bulb needs it turned to "8," the first bulb is far more sensitive to dimming (more potent inhibitor at work). In drug development, this is like comparing two sedatives: if Drug A puts someone at half-drowsiness at 5mg while Drug B needs 50mg to do the same job, Drug A is ten times more potent (IC50 of 5mg vs 50mg). But here's the critical nuance—this tells you nothing about whether either drug can actually put someone fully to sleep. A drug might be incredibly potent at hitting the halfway mark but useless at going further. That's why IC50 measures potency, not efficacy. In cPNI, when comparing anti-inflammatory botanicals like Curcumin versus synthetic NSAIDs, we're asking: "What concentration dims the inflammatory fire to exactly half?" Lower numbers mean more bang for your therapeutic buck.
IC50 is determined through systematic dose-response experiments following this cascade:
Experimental Protocol:
- Target selection (enzyme, receptor, cell function, pathogen)
- Serial dilution of test compound (typically 6-10 concentrations spanning 3-4 orders of magnitude)
- Incubation with target system (time and conditions standardized)
- Measurement of biological effect (% inhibition vs control)
- Mathematical curve fitting to sigmoidal dose-response equation
Mathematical Derivation:
The relationship follows the Hill equation:
% Inhibition = (100 × [Drug]^n) / (IC50^n + [Drug]^n)
where n = Hill coefficient (slope of curve)
Key Mechanistic Points:
- At IC50 concentration: exactly 50% of targets are inhibited/bound
- Below IC50: majority of targets remain active (minimal therapeutic effect)
- Above IC50: increasing proportion of targets inhibited (approaching Emax)
- The IC50 value shifts based on:
- Receptor/enzyme affinity (Ki, Kd)
- Competition (substrate concentration, endogenous ligands)
- Cellular context (transport, metabolism, compartmentalization)
graph TD
A[Test Compound] --> B{Dose Range}
B --> C["Low Dose<br/>IC50/10"]
B --> D[IC50 Dose]
B --> E["High Dose<br/>10×IC50"]
C --> F[10-20% Inhibition]
D --> G["50% Inhibition<br/>TARGET MEASURE"]
E --> H[80-95% Inhibition]
G --> I["Calculate IC50<br/>from sigmoid curve"]
I --> J{Interpretation}
J --> K["Low IC50<br/>nM range<br/>HIGH POTENCY"]
J --> L["Mid IC50<br/>μM range<br/>MODERATE POTENCY"]
J --> M["High IC50<br/>mM range<br/>LOW POTENCY"]
style D fill:#e1f5ff
style G fill:#ffe1e1
style K fill:#d4edda
Receptor-Specific Example (COX-2 Inhibition):
Aspirin → Acetylates COX-2 Ser530 → Irreversible inhibition → IC50 ~1.7 μM
Curcumin → Competitive COX-2 active site binding → Reversible inhibition → IC50 ~1.8 μM
Resolvins → Different mechanism (no COX inhibition, but resolution pathway activation)
The IC50 does NOT indicate:
- Maximum achievable effect (Emax)
- Binding reversibility (competitive vs non-competitive)
- In vivo efficacy (affected by bioavailability, metabolism, tissue distribution)
- Clinical therapeutic dose (requires additional PK/PD modelling)
IC50 is foundational to evidence-based cPNI intervention design and supplement selection:
Clinical Application Framework:
-
Comparing Therapeutic Options:
- Resolvins (RvD1 IC50 for neutrophil migration: ~1 nM) vs Aspirin (platelet aggregation IC50: ~3 μM)—thousand-fold potency difference
- Omega-3 fatty acids conversion to SPMs creates low-IC50 resolution mediators vs parent fatty acid effects (high-IC50)
- This explains why 4g EPA/DHA may be needed but only nanomolar RvD1 concentrations are effective
-
Evolutionary Mismatch Context:
-
Metamodel Integration:
-
Clinical Thresholds:
- Therapeutically relevant IC50 must be achievable in target tissue
- Plasma concentration rule: aim for 5-10× IC50 for clinical effect (accounts for protein binding, metabolism)
- Example: Atorvastatin IC50 for HMG-CoA reductase: 8 nM; typical dose achieves ~40 nM plasma level
-
Intervention Decisions:
- Low IC50 + poor bioavailability = clinical futility (e.g., Curcumin without piperine)
- High IC50 + excellent tissue penetration = may still be effective (e.g., Vitamin C as antioxidant)
- IC50 in vitro ≠IC50 in vivo (metabolic activation required: Aspirin → salicylic acid)
Patient Selection Implications:
- Potency hierarchy: IC50 in nM (nanomolar) >> μM (micromolar) >> mM (millimolar)—1000-fold difference per step
- RvD1 inhibits neutrophil transmigration at IC50 ~0.1-1 nM (one of nature's most potent anti-inflammatory signals)
- Aspirin acetylates COX-1 irreversibly: IC50 ~1.7 μM; COX-2: IC50 ~278 μM (165-fold less potent for COX-2)
- IC50 shifts with substrate concentration: competitive inhibitors show higher IC50 when substrate levels rise (clinical implication: inflammation may reduce drug potency)
- Temperature-dependent: IC50 measured at 37°C may not reflect actual body site temperature (e.g., skin, extremities)
- Atorvastatin IC50: ~8 nM for HMG-CoA reductase; clinical dose: 10-80mg achieves ~20-160 nM plasma (2-20× IC50)
- Exam pearl: IC50 ≠therapeutic dose—must account for bioavailability, protein binding (free drug fraction), tissue distribution, and metabolic stability
- In vitro IC50 typically 10-100× lower than in vivo effective concentration (First Pass Effect, tissue barriers)
- Combination therapies may show synergistic IC50 reduction: Curcumin + Piperine (20-fold bioavailability increase = functional IC50 reduction)
- Resolvins and Protectins maintain low IC50 even at nanomolar concentrations due to GPR receptor amplification cascade
- Irreversible inhibitors (Aspirin on COX-1) effectively have "functional IC50" dependent on target synthesis rate, not drug concentration